

# Quinoline-Substituted 1,2,3-Triazole-Based Molecules, As Promising Conjugated Hybrids in Biomedical Research



Luz Karime Luna Parada<sup>1</sup>, Leonor Yamile Vargas Méndez<sup>2</sup> and Vladimir V Kouznetsov<sup>1\*</sup>

<sup>1</sup>Laboratorio de Química Orgánica y Biomolecular, CMN, Universidad Industrial de Santander, Parque Tecnológico Guatiguara, Piedecuesta, Colombia

<sup>2</sup>Grupo de Investigaciones Ambientales para el Desarrollo Sostenible, Facultad de Química Ambiental, Universidad Santo Tomás, Bucaramanga, Colombia

Submission: May 29, 2018; Published: June 07, 2018

\*Corresponding author: Vladimir V Kouznetsov, Laboratorio de Química Orgánica y Biomolecular, CMN, Universidad Industrial de Santander, Parque Tecnológico Guatiguara, Km 2 vía refugio, Piedecuesta, A.A. 681011, Colombia, Email: vkuznechnik@gmail.com

## Abstract

Building a single molecular framework containing quinoline and triazoles rings of promising biological activity through molecular hybridization strategy offers the viewpoint of better drugs for the treatment of a number of diseases including cancer, malaria, tuberculosis and other illnesses. Presenting modified selectivity profile, different and/or dual modes of action and reduced undesired side effects, these molecular hybrids are gaining momentum worldwide showing their promise in drug discovery. Such hybrid molecules are usually made efficiently through click chemistry technique using multicomponent reactions. In this paper, we discuss chemistry and biology of some quinoline-substituted 1,2,3-triazole hybrids aiming at a better understanding of physicochemical properties of quinoline-triazole hybrids for designing novel bioactive chemical entities. So, principal Lipinski' parameters and *in silico* study (lipophilicity and molecular polar surface area) are also briefly mentioned and applied to selected quinoline-1,2,3-triazole hybrids. The mini-review is divided in two general parts: synthetic aspects of the preparation of these hybrids and their pharmacological aspects paying attention to the widespread dangerous diseases such as malaria, cancer, and human fungal infections, especially systemic mycoses.

**Keywords:** Molecular Hybridization; Quinoline-1,2,3-triazole Hybrids; Lipinski' Parameters and *in silico* Study; Azide-Alkyne Cycloaddition Reactions; Cancer; Malaria; Candidiasis

**Abbreviations:** CQ: Cloroquinine; Qu: Quinoline; TA: Triazoles; PhM: Pharmacophoric Molecule; CuAAC: Copper-Catalyzed Azide-Alkyne Cycloaddition Reactions; NaAsc: Sodium Ascorbate; CRT: Chloroquine Resistance Transporter; PfCRT: *P. falciparum* Chloroquine Resistance Transporter; TPSA: Molecular Polar Surface Area; GPCR: G Protein-Coupled Receptor

## Introduction

The molecular hybridization of biologically active molecules is a powerful strategy for rational design of new ligands or prototypes based on the recognition of pharmacophoric sub-unities in the molecular structure of two or more known bioactive derivatives which, through the adequate fusion of these sub-unities, lead to the drawing of new hybrid architectures that maintain pre-selected characteristics of the original templates [1,2]. Nowadays, it is well recognized that the main goals for exploiting the hybridization techniques for drug design are; 1) to achieve improved activity, 2) to gain higher selectivity, 3) to lower toxicity of drugs. Some of the pharmacological properties exerted by molecular hybrids of N-heterocycles comprise remarkable applications for drug treatment of serious life-threatening conditions such as cancer [3], bacterial or protozoan infections [4-6] and others. Additionally,

such combination of two structurally different heterocycles in a single molecule to form molecular hybrids, e.g. heterobifunctional molecules, with improved biological profile could be the suitable and practical solution to stop or slow down the spread of drug resistance [7]. As result, so-called molecules with "two heads" have become very popular [8]. Generally, these molecules are classified in three types: merged, fused and conjugated molecular hybrids. Merged hybrids are those contain underlying two pharmacophores. When these pharmacophores exist as unique parts without superposition, molecules are called fused hybrids. Finally, conjugated hybrids (molecular conjugates) are usually separated by a discrete linker (or space) group that is not found in either of the selective sub-unit [9,10] (Figure 1). These latter hybrids are in the center of our mini-review.




Figure 1: General aspects of molecular hybrids.

Among numerous N-heterocycles, quinolines and 1,2,3-triazoles are two important classes of small heterocyclic molecules, which have a wide range of chemotherapeutic uses. Remarkably, while quinoline molecules are present commonly in living organisms as important secondary metabolites [11], the 1,2,3-triazoles, chemically inert compounds, have not been detected in naturally occurring products [12]. Nevertheless, both quinoline and 1,2,3-triazole skeletons form part in diverse and numerous conjugated hybrids, valuable biomolecules for drug

development. This molecular diversity comes from the multiple possibilities of the combination between quinoline (Qu) and 1,2,3-triazole (TA) nucleus. First, there are three possibilities to connect TA ring with Qu skeleton: 1-(quinolinyl)-1,2,3-triazoles, 4-(quinolinyl)-1,2,3-triazoles and 5-(quinolinyl)-1,2,3-triazoles. Moreover, 1,2,3-TA can act as pharmacophores (Figure 2A) and linkers between quinoline and other pharmacophoric molecules (PhM) (Figure 2B) of interest in molecular hybridization approaches [13,14] (Figure 2).





Figure 2: Types of conjugated quinoline-1,2,3-triazole hybrids.

In this work, we discuss chemistry and biology of some quinoline-substituted 1,2,3-triazole hybrids reported as potent biological agents. Principal Lipinski' parameters and *in silico* study are also briefly mentioned and applied to selected quinoline-1,2,3-triazole hybrids. Therefore, this mini-review aims at a better understanding of physicochemical properties of quinoline-triazole hybrids for designing novel bioactive chemical entities. The mini-review is divided in two general parts: synthetic aspects of the synthesis of these hybrids and their pharmacological aspects paying attention to the widespread dangerous diseases such as malaria, cancer, and human fungal infections, especially systemic mycoses.

### Synthetic Aspects

One of the most important and practical approaches to the 4-(quinolinyl)-1,2,3-triazoles 3 is the modified Huisgen reaction between quinoline 1 with terminal alkyne moiety and an

organoazide 2 through a catalytic 1,3-dipolar cycloaddition process [15] (Figure 3A). Noteworthy, that the Huisgen reaction, which occurs without any catalysts, gives poorly only a regioisomeric mixture of products that reduced its practical application [16], while Meldal and Fokin-Sharpless modified protocols [17,18] that use copper catalysts (CuI, CuBr, CuSO<sub>4</sub>, Cu<sub>2</sub>O), allow obtaining exclusively 1,4-disubstituted 1,2,3-triazoles, e.g. 4-(quinolinyl)-1,2,3-triazoles 3 in very high yields. Another approach to obtain similar 1,4-disubstituted 1,2,3-triazoles, e.g. 1-(quinolinyl)-1,2,3-triazoles 7 consists in cycloaddition reactions between terminal alkynes such as alkynes 5 and quinoline-azides 6 under the same condition reactions (Figure 3B). In general, sub-product, 1,5-disubstituted 1,2,3-triazoles 4 and 8 could be regioselectively obtained using ruthenium cyclopentadienyl complex (Cp\*RuCl(PPh<sub>3</sub>)<sub>2</sub>) as catalyst [19]. However, this version of Huisgen cycloaddition reaction has not yet been applied widely and these Qu-TA hybrids were not obtained (Figure 3).



**Figure 3:** Direct synthesis of quinoline-substituted 1,2,3-triazoles via CuAAC reaction.


So-called “click” copper-catalyzed azide-alkyne cycloaddition reactions (CuAAC) have become the focus of many chemists and were found wide application in drug synthesis, chemical biology, among others.

Some synthetic aspects of this reaction should be taken into consideration before the preparation of desired quinoline-substituted 1,2,3-triazole hybrids 3 and 7 [15]:

- i. The standard protocol, which consists in using the cost-efficient salt  $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$  (or  $\text{Cu}(\text{OAc})_2 \cdot \text{H}_2\text{O}$ ) and ascorbic acid (sodium ascorbate, NaAsc), is usually realized in a mixture of water and alcohol as solvent (“Sharpless-Fokin conditions”). Water, in combination with other alcohols (MeOH, *t*-BuOH), THF, DMF, and DMSO, could all be employed as co-solvents for this cycloaddition reaction, enabling a wide range of substrates to be adapted;
- ii. Alkynyl quinolines 1, common key intermediates in this transformation, are not available and must be prepared from hydroxy-quinoline derivatives and others;
- iii. To improve the utility and manipulability of this process for generation of desired products 3, a microwave-assisted

three-component reaction of alkyl halides, sodium azide, and alkynyl quinolines is developed.

To obtain O-alkynoxyquinolines 11, respective hydroxyquinolines (mainly, 4(8)-hydroxyquinoline derivatives 9 and 10) are O-alkylated using propargyl bromide 8 or its analogs. Subsequently, solutions of the O-alkynyl- oxyquinolines obtained are usually treated with respective pre-formed azides 12 [20] or *in situ* forming organoazides from alkyl bromides 13 and  $\text{NaN}_3$  under reaction condition described above or in an alternative solvents, e.g. PEG-400 [21] that give hybrid products 14,15 in good yields (Figure 4). Noteworthy, that while some 8-hydroxyquinoline derivatives are commercially available, 4-hydroxyquinolines (quinolin-4-ones) must be prepared using common Gould-Jacobs or Conrad-Limpach protocols. In contrast, synthesis of Qu-TA-based on aminoquinolines 20 (mostly, 4-aminoquinoline derivatives) starts with the reaction between 4-chloro (bromo) quinolines 16 and propargyl amine or its derivatives 17 to give N-alkynylaminoquinolines 18. This reaction needs prolonged heating (until 63 h) in a sealed tube at 110 °C. Moreover, applying a CuACC reaction ( $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}/\text{NaAsc}$ , *tert*-BuOH-water 1:1, 40 °C) between alkynes 18 and aryl azides 19, final hybrids products 20 are formed in poor to moderate yields [22] (Figure 5).



**Figure 4:** General synthesis of Qu-TA-based on hydroxyquinoline scaffolds.



Another green aspect of CuAAC reaction is the application of glycerol as solvent in the synthesis of 1,2,3-triazoles using a three-component reaction of organic halides, terminal acetylenes, and sodium azide. Like water, glycerol is also naturally available, highly hydrophilic, environmentally friendly, and inexpensive. Thus, a variety of 1,2,3-triazoles were prepared in good to excellent yields (37-99%) with this green solvent. The published procedure involves the use of CuI and diethylamine, which are two easily available reagents as the new catalytic system at room temperature. This simple and low-cost protocol exhibits wide substrate scope and ambient reaction condition and can be easily used for large-scale preparation [26]. Both environmental implementations in this reaction could serve in the synthesis of new Qu-1,2,3-TA hybrids. These multicomponent reactions and/or click chemistry are important synthetic tools to synthesize such hybrids.


### Pharmacological Aspects

Recently obtained 1,2,3-triazole-appended quinolines, including 4-(quinolinyl)-1,2,3-triazole and 1-(quinolinyl)-1,2,3-triazole hybrids as promising lead compounds with large spectra of pharmacological effects, stimulate their further biological investigation. The triazole functionality are usually introduced into privileged N-heterocycles like quinolines because of its favorable properties, including bridge moderate dipole character,

hydrogen bonding capability, rigidity and stability under *in vivo* conditions, which are evidently responsible for their diverse biological activities. Such molecular hybrids could be very suitable in the solution of multiple drugs resistance in malaria, especially chloroquine (CQ)-resistant *P. falciparum* which emergence and spread are the major obstacles in the control of this disease.

Malaria remains one of the most serious infectious diseases; it threatens nearly half of the world's population and led to hundreds of thousands of deaths in 2015, predominantly among children in Africa. Thus, based on general accepted resistance mechanism, which involves two integral membrane proteins, localized in the parasite's digestive vacuole membrane; - plasmodial P-glycoprotein homolog1 (Pgh1) and CQ resistance transporter (CRT) [10,27], conjugated molecules derived from CQ may be less efficiently extruded by CQ-resistant *P. falciparum*, having some enzyme effect that prevents them from fitting into the substrate binding site of *P. falciparum* chloroquine resistance transporter (PfCRT).

Some of such conjugated molecules are 1H-1,2,3-triazole-tethered 7-chloroquinoline-isatin hybrids. The compound 31 with an optimum combination of longer alkyl chain length and chloro substituent at C-5 position of isatin ring displayed the best activity with  $IC_{50}$  value of 1.21  $\mu$ M against the CQ-resistant *P. falciparum* W2 strain [28] (Figure 8).



It is well-known that the pharmacological activity of some compounds is strictly related to its hydrophilic/lipophilic nature because to display therapeutic properties they must pass through

a series of biological barriers, from the administration site to the site of action.

Therefore, from the physicochemical properties of biologically active compounds, lipophilicity (expressed in LogP, where P is the octanol/water partition coefficient) and molecular polar surface area (TPSA) are major descriptors of great importance and should be determined from the early stages of drug development because they affect basic steps of a drug's pharmacokinetics and pharmacodynamics, such as absorption, including intestinal absorption, bioavailability, Caco-2 permeability and blood-brain barrier penetration (Lipinski's Rule of 5 and Veber's criteria), as well as compound-receptor interactions score for the most important drug targets.

These properties could be easily calculated by diverse software available online. Paying attention to the importance of knowing these physicochemical properties, we used Molinspiration software [29] for the 1,2,3-triazole-tethered 7-chloroquinoline-isatin 31 and chloroquine, historical antimalarial drug. Analyzing the results obtained, it can be noted that hybridization of CQ with 5-chloro-isatin linked by 1,2,3-triazole ring produced a drastic change in the calculated lipophilicity, cLogP (miLogP from Molinspiration software) and TPSA parameter (Figure 8).

According to the cLogP values, both quinoline compounds show high bioavailability properties. However, hybrid 31 is a molecule less lipophilic (cLogP = 3.29) than chloroquine (cLogP = 5.00). On the other hand, while TPSA values predict a very good bioavailability for chloroquine (TPSA = 28.16), TPSA parameter of hybrid 31 are higher (TPSA = 94.71) that suggests that this chloroquinoline-isatin hybrid could have some problems of the absorption and barrier penetration. Additionally, according to the predicted bioactivity score, hybridization of CQ with 5-chloro-isatin linked by 1,2,3-triazole ring makes to switch biological targets: while chloroquine would affect G protein-coupled receptor (GPCR), ion channels and kinases, hybrid 31 would work as an enzyme and/or kinase inhibitor. These theoretical results evince that Qu-TA hybrid formation is a valuable approach in the development of novel antimalarial (lead) compounds [30,31].

Derivatization of the hydroxyl group from 8-hydroxyquinoline by attaching a 1,2,3-triazole ring presents a good strategy for searching novel molecules against cancer cell lines, because both 8-hydroxyquinoline (or its derivatives) and 1,2,3-triazoles showed interesting cytotoxic properties [32-34]. For example, Clioquinol (5-chloro-7-iodo-8-hydroxyquinoline, CIHQ) and Nitroquinoline (8-hydroxy-5-nitroquinoline) have been shown to have anticancer activity both *in vitro* and *in vivo* [35,36]. The latter hydroxyquinoline is more potent than the CIHQ suggesting that it may be useful in treating cancer [37]. Moreover, the simple 8-hydroxy-2-quinolinecarbaldehyde showed also potent *in vitro* cytotoxicity against the human cancer cell lines [38].


That is why, it is not surprising that new hybrids are available, but it is shocking that so far examples are rare. In 2014, evaluating *in vitro* for the antiproliferative activity on various cancer cell types: U251 (glioma, CNS), MCF-7 (breast), NCI-ADR/RES (ovarian

expressing phenotype multiple drugs resistance), 786-0 (kidney), NCI-H460 (lung, non-small cells), PC-3 (prostate) and OVCAR-03 (ovarian), Alves and co-workers reported at the first time that 4-(quinolinyl)-1,2,3-triazole hybrids based on 8-hydroxyquinoline skeleton and 1,2,3-TA ring containing aromatic or protected sugar moieties should be explored as anticancer agents [39]. Two of these hybrids, trichlorobenzyl-1H-1,2,3-triazol-4-yl-quinoline 32 and  $\alpha$ -D-galactopyranosyl-1H-1,2,3-triazol-4-yl-quinoline 33 disclosed potent and selective antiproliferative activity, expressed in 50% cell growth inhibition or a cytostatic effect ( $GI_{50}$ ) (Figure 9).

The first, "more simple" hybrid 32 showed potent activity against prostate cell lines (PC-3,  $GI_{50}$  = 2.8 mg/mL) compared with activity of Doxorubicin (Adriamycin) ( $GI_{50}$  = 3.8 mg/mL), used in oncologic practice since the late 1960s. However, this hybrid possesses poor selectivity index (SI) value of 1.9 regarding normal cells, human keratinocytes (HaCat). Second hybrid 33 exhibited remarkable  $GI_{50}$  value ( $GI_{50}$  < 0.25 mg/mL) against ovarian cancer (OVCAR-03) cells, indicating that it was even more active than Doxorubicin ( $GI_{50}$  = 0.43 mg/mL). This hybrid presented the high selectivity with SI value of >117.6 for ovarian cancer cell that suggests the potential use of this compound for future *in vivo* tests. However, it showed weak antiproliferative activity against other cancer cell lines.

The physicochemical parameters of the selected hybrids 32,33, Doxorubicin as reference anticancer drug and probable enzyme activity scores for the most important drug targets obtained through Molinspiration software [29], gave an interesting information that should be commented:

- a) Doxorubicin, natural antitumor antibiotic, is a tetracyclic molecule with much less lipophilic property (cLogP = 0.57), e.g. with good H<sub>2</sub>O solubility, while hybrid compounds 32,33 are more lipophilic molecules (cLogP = 3.42-5.82);
- b) Between these hybrid molecules there is only a structural difference (trichlorobenzyl fragment versus protected sugar moiety), which is responsible for their molecular properties;
- c) Although both hybrids showed a potent *in vitro* antiproliferative activity overcoming activity of Doxorubicin, their TPSA values specify some problems of the absorption and barrier penetration;
- d) Chemical nature of second pharmacophores in these hybrids makes to change biological targets predicting GPCR ligand capacity for compound 32 and kinase inhibitor property for hybrid 33 indicating that these compounds would possess diverse mode of antitumor action. Interestingly, predicted drug-receptor interactions for Doxorubicin are more pronounced and very different to those of hybrids 32,33 (Figure 9).
- e) This simple and brief analysis could help to design better new Qu-1,2,3-TA hybrids with antitumor properties.



**Figure 9:** 4-(Quinolonyl)-1,2,3-triazole hybrids as potential anticancer agents.

The frequency of human fungal infections has increased drastically worldwide, in particular, systemic mycoses that are very difficult to diagnose and treat [40]. Cancer patients with metastasis, AIDS patients infected by HIV and organ transplant patients, all these immunocompromised patients have a high probability of invasive fungal infections, especially opportunistic invasive mycoses like candidiasis [41]. It is well-known that within the limited antifungal drug collection, the azole antifungals are the most frequent class used to treat *Candida* infections and one of the most commonly prescribed antifungal drugs used for most *C. albicans* infections is Fluconazole, a small molecule based on two 1H-1,2,4-triazole rings (Figure 10).

As Fluconazole (FLC) is fungistatic rather than fungicidal, the treatment provides the opportunity for acquired resistance to develop in the presence of this antifungal [42]. Therefore, there is

a need for developing antifungal agents with novel structure and mode of action. In this context, quinoline-substituted 1,2,3-triazole-based molecules are suitable models. Abid and co-workers at the first time designed and synthesized 8-hydroxyquinolines bearing 1,2,3-triazole ring as potent inhibitors of *Candida* species [43,44]. Their research showed that two hybrids of this type, **34** and **35** (Figure 10) have potent IC<sub>50</sub> values for *C. albicans* ATCC 90028 (standard) and *C. albicans* D15.9 (fluconazole resistant) strains and significant inhibitory effect on the growth of FLC-sensitive as well as FLC-resistant *C. albicans* strains (Table 1). Interestingly, growth curve and time kill curve studies indicated that hybrid **34** has fungicidal nature while compound **35** was fungistatic. Curiously, Fluconazole is fungistatic and may be fungicidal, depending on the concentration. Moreover, both hybrid compounds showed significant inhibition in ergosterol biosynthesis like does Fluconazole.

**Table 1:** Anti-*Candida* activity and antifungal susceptibility using disk diffusion assay for hybrids 33,34 and Fluconazole.

	Anti- <i>Candida</i> Activity, IC <sub>50</sub> , μg/mL	Antifungal Susceptibility (Zone of Inhibition, mm)		
	<i>C. albicans</i> ATCC90028	<i>C. albicans</i> ATCC 90028 (Standard)	<i>C. albicans</i> D15.9 (FLC-Resistant)	<i>C. albicans</i> D27 (FLC-Susceptible)
34	0.044	35	26	19
35	25.4	18	15	16
FLC	15.62	26	24	27




Figure 10: 4-(Quinoliny)-1,2,3-triazole hybrids as potential antifungal agents.

Noteworthy, that both compounds 34 and 35 were significantly less cytotoxic than Fluconazole. Analyzing their physicochemical properties obtained *in silico* study, we could note that calculations predict negative partition coefficient values ( $c\text{LogP} = -0.12$ ) of Fluconazole indicating that its very high solubility, while both hybrid compounds 34, 35 possess appropriate  $c\text{LogP}$  values ( $c\text{LogP} < 5$ ) according to the Lipinski's rule. Interestingly, in practice, Fluconazole, white crystalline solid is slightly soluble in water, but has high oral efficacy caused by high solubility in gastric juice [45]. When  $c\text{LogP}$  and TPSA parameters for these hybrids are compared, the role of chlorine atom, present in quinoline ring (comp. 35), can be seen: the presence of Cl enhances lipophilicity, but does not change polar surface area of the molecule although chlorine atom is highly electronegative atom.

Another interesting detail is that these hybrids would affect various receptor interactions, whereas the predicted FLC-receptor interaction scores are minimal. However, it should be commented that there are plenty of examples available for such prediction violation amongst the existing drugs. Precisely, majority of violations come from antifungals and others like antibiotics, vitamins, and cardiac glycoside [46].

## Conclusion

The molecular hybridization strategy offers the possibility of building a single molecular framework containing quinoline and triazoles rings with modified selectivity profile, different and/or dual modes of action and reduced undesired side effects. These molecular hybrids are especially interesting for the development of new prototypes in the treatment of cancer and parasitic diseases including malaria, protozoan and fungal infections. Due to synthetic versatility of catalyzed azide-alkyne cycloaddition reactions, it can be expected that these efficient reactions and rational design based on *in silico* study could provide diverse novel quinoline-triazole prototypes for innovating drugs in the near future. It is evident that the future is optimistic and that this type of design will lead to important anticancer and antiparasitic drugs with higher activity, better selectivity and lower toxicity than the traditional combination therapies.

## References

- Beruvé G (2016) An overview of molecular hybrids in drug discovery. *Expert Opin Drug Discov* 11 (3): 281-305.
- Viegas-Junior C, Danuello A, da Silva Bolzani V, Barreiro EJ, Fraga CAM (2007) Molecular hybridization: a useful tool in the design of new drug prototypes. *Curr Med Chem* 14(17): 1829-1852.

3. Nepali K, Sharma S, Sharma M, Bedi PMS, Dhar KL (2014) Rational approaches, design strategies, structure activity relationship and mechanistic insights for anticancer hybrids. *Eur J Med Chem* 77: 422-487.
4. Xiao ZP, Wang XD, Wang PF, Zhou Y, Zhang JW, et al. (2014) Design, synthesis, and evaluation of novel fluoroquinolone-flavonoid hybrids as potent antibiotics against drug-resistant microorganisms. *Eur J Med Chem* 80: 92-100.
5. Cavalli A, Bolognesi ML (2009) Neglected tropical diseases: multi-target-directed ligands in the search for novel lead candidates against *Trypanosoma* and *Leishmania*. *J Med Chem* 52(23): 7339-7359.
6. Hu YQ, Gao C, Zhang S, Xu L, Xu Z, et al. (2017) Quinoline hybrids and their antiplasmodial and antimalarial activities. *Eur J Med Chem* 139: 22-47.
7. Corson TW, Aberle N, Crews CM (2008) Design and applications of bifunctional small molecules: why two heads are better than one. *ACS Chem Biol* 3(11): 677-692.
8. Saadeh HA, Mubarak MS (2017) Hybrid Drugs as Potential Combatants Against Drug-Resistant Microbes: A Review. *Curr Top Med Chem* 17(8): 895-906.
9. Morphy R, Rankovic Z (2005) Designed Multiple Ligands. An Emerging Drug Discovery Paradigm. *J Med Chem* 48(21): 6523-6543.
10. Kouznetsov VV (2013) New Quinoline-based Multiple Ligands in Antimalarial Drug Development. In Banet AC, Brassier PE (Eds.), *Antimalarial Drug Research and Development Nova Biomedica*, New York, USA, pp. 69-128.
11. Chung PY, Bian ZX, Pun HY, Chan D, Chan ASC, et al. (2015) Recent advances in research of natural and synthetic bioactive quinolines. *Future Med Chem* 7(7): 947-967.
12. Faraz KM, Garima V, Wasim A, Akranth M, Mumtaz AM, et al. (2017) Synthetic Trends Followed for the Development of 1,2,3-Triazole Derivatives. *Inter J Drug Develop Res* 9(2): 22-25.
13. Agalave SG, Maujan SR, Pore VS (2011) Click chemistry: 1,2,3-triazoles as pharmacophores. *Chem Asian J* 6(10): 2696-2718.
14. Dhee D, Singh V, Shankar R (2017) Medicinal attributes of 1,2,3-triazoles: Current developments. *Bioorg Chem* 71: 30-54.
15. Kouznetsov VV, Vargas Méndez LI, Zubkov F (2017) Recent Advances in the Synthesis of Bioactive Quinoline-Based 1, 2, 3-Triazoles via Cu-Catalyzed Huisgen 1, 3-Dipolar Cycloaddition ("Click Reaction"). *Mini Rev Org Chem* 13(6): 488-503.
16. Huisgen R (1963) 1, 3-Dipolar cycloadditions. Past and future. *Angew Chem Int Ed Engl* 2(10): 565-598.
17. Tornøe CW, Christensen C, Meldal M (2002) Peptidotriazoles on Solid Phase: [1,2,3]-Triazoles by Regiospecific Copper(I)-Catalyzed 1,3-Dipolar Cycloadditions of Terminal Alkynes to Azides. *J Org Chem* 67(9): 3057-3064.
18. Rostovtsev VV, Green LG, Fokin VV, Sharpless KB (2002) A stepwise Huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes. *Angew Chem Int Ed* 41(14): 2596-2599.
19. Rasmussen LK, Boren BC, Fokin VV (2007) Ruthenium-Catalyzed Cycloaddition of Aryl Azides and Alkynes. *Org Lett* 9(26): 5337-5339.
20. Irfan M, Aneja B, Yadava U, Khan SI, Manzoor N, et al. (2015) Synthesis, QSAR and anticandidal evaluation of 1,2,3-triazoles derived from naturally bioactive scaffolds. *Eur J Med Chem* 93: 246-254.
21. Garudachari B, Isloor AM, Satyanarayana MN, Fun HK, Hegde G (2014) Click chemistry approach: Regioselective one-pot synthesis of some new 8-trifluoromethylquinoline based 1,2,3-triazoles as potent antimicrobial agents. *Eur J Med Chem* 74: 324-332.
22. Fisher GM, Tanpure RP, Douchez A, Andrews KT, Poulsen SA (2014) Synthesis and Evaluation of Antimalarial Properties of Novel 4-Aminoquinoline Hybrid Compounds. *Chem Biol Drug Des* 84(4): 462-472.
23. Pereira GR, Brandão GC, Arantes LM, de Oliveira Jr HA, de Paula RC, et al. (2014) 7-Chloroquinolinotriazoles: Synthesis by the azide-alkyne cycloaddition click chemistry, antimalarial activity, cytotoxicity and SAR studies. *Eur J Med Chem* 73: 295-309.
24. Tireli M, Maračić S, Lukin S, Kulcsár MJ, Žilić D, et al. (2017) Solvent-free copper-catalyzed click chemistry for the synthesis of N-heterocyclic hybrids based on quinoline and 1, 2, 3-triazole. *Beilstein J Org Chem* 13: 2352.
25. Andersen J, Mack J (2018) Mechanochemistry and organic synthesis: from mystical to practical. *Green Chem* 20(7): 1435-1443.
26. Guo S, Zhou Y, Dai B, Huo C, Liu C, et al. (2018) CuI/Et<sub>3</sub>NH-Catalyzed One-Pot Highly Efficient Synthesis of 1, 4-Disubstituted 1, 2, 3-Triazoles in Green Solvent Glycerol. *Synthesis* 50(11): 2191-2199.
27. Petersen I, Eastman R, Lanzer M (2011) Drug-resistant malaria: Molecular mechanisms and implications for public health. *FEBS Lett* 585(11): 1551-1562.
28. Raj R, Singh P, Singh P, Gut J, Rosenthal PJ, et al. (2013) Azide-alkyne cycloaddition en route to 1H-1, 2, 3-triazole-tethered 7-chloroquinoline-isatin chimeras: synthesis and antimalarial evaluation. *Eur J Med Chem* 62: 590-596.
29. <http://www.molinspiration.com>
30. Vandekerckhove S, Dhooghe M (2015) Quinoline-based antimalarial hybrid compounds. *Bio org Med Chem* 23(16): 5098-5119.
31. Hu YQ, Gao C, Zhang S, Xu L, Xu Z, et al. (2017) Quinoline hybrids and their antiplasmodial and antimalarial activities. *Eur J Med Chem* 139: 22-47.
32. Oliveri V, Vecchio G (2016) 8-Hydroxyquinolines in medicinal chemistry: A structural perspective. *Eur J Med Chem* 120: 252-274.
33. Xu H, Chen W, Zhan P, Liu X (2015) 8-Hydroxyquinoline: a privileged structure with a broad-ranging pharmacological potential. *Med Chem Comm* 6(1): 61-74.
34. Prachayasittikul V, Pingaew R, Anuwongcharoen N, Worachartcheewan A, Nantasenamat C, et al. (2015) Discovery of novel 1, 2, 3-triazole derivatives as anticancer agents using QSAR and in silico structural modification. *Springer Plus* 4(1): 571.
35. Oliveri V, Giuffrida ML, Vecchio G, Aiello C, Viale M (2012) Gluconjugates of 8-hydroxyquinolines as potential anti-cancer prodrugs. *Dalton Trans* 41(15): 4530-4535.
36. Cao B, Li J, Zhou X, Juan J, Han K, et al. (2014) Cloiquinol induces pro-death autophagy in leukemia and myeloma cells by disrupting the mTOR signaling pathway. *Sci Rep* 4: 5749.
37. Jiang H, Taggart JE, Zhang X, Benbrook DM, Lind SE, et al. (2011) Nitroxoline (8-hydroxy-5-nitroquinoline) is more a potent anti-cancer agent than cloiquinol (5-chloro-7-iodo-8-quinoline). *Cancer Lett* 312(1): 11-17.
38. Chan SH, Chui CH, Chan SW, Kok SH, Chan D, et al. (2013) Synthesis of 8-hydroxyquinoline derivatives as novel antitumor agents. *ACS Med Chem Lett* 4(2):170-174.
39. De O Freitas LB, Borgati TF, de Freitas, RP, Ruiz AL, Marchetti GM, et al. (2014) Synthesis and antiproliferative activity of 8-hydroxyquinoline derivatives containing a 1,2,3-triazole moiety. *Eur J Med Chem* 84: 595-604.
40. Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, et al. (2012) Hidden killers: human fungal infections. *Sci Transl Med* 4(165): 165rv13.

41. Whaley SG, Berkow EL, Rybak JM, Nishimoto AT, Barker KS, et al. (2017) Azole antifungal resistance in *Candida albicans* and emerging non-*albicans* *Candida* species. *Front Microbiol* 7: 2173.
42. Berkow EL, Lockhart SR (2017) Fluconazole resistance in *Candida* species: a current perspective. *Infect Drug Resis* 10: 237-245.
43. Irfan M, Aneja B, Yadava U, Khan SI, Manzoor N, et al. (2015) Synthesis, QSAR and anti-*Candida* evaluation of 1,2,3-triazoles derived from naturally bioactive scaffolds. *Eur J Med Chem* 93: 246-254.
44. Irfan M, Alam S, Manzoor N, Abid M (2017) Effect of quinoline based 1,2,3-triazole and its structural analogues on growth and virulence attributes of *Candida albicans*. *PLoS One* 12(4): e0175710.
45. Park HJ, Kim MS, Lee S, Kim JS, Woo JS, et al. (2007) Recrystallization of fluconazole using the supercritical antisolvent (SAS) process. *Inter Journal Pharm* 328(2): 152-160.
46. Kadam RU, Roy N (2007) Recent trends in drug-likeness prediction: A comprehensive review of *In silico* methods. *Indian J Pharm Sci* 69(5): 609-615.



This work is licensed under Creative Commons Attribution 4.0 License  
DOI: [10.19080/OMCIJ.2018.07.555708](https://doi.org/10.19080/OMCIJ.2018.07.555708)

**Your next submission with Juniper Publishers  
will reach you the below assets**

- Quality Editorial service
- Swift Peer Review
- Reprints availability
- E-prints Service
- Manuscript Podcast for convenient understanding
- Global attainment for your research
- Manuscript accessibility in different formats  
**( Pdf, E-pub, Full Text, Audio )**
- Unceasing customer service

**Track the below URL for one-step submission**  
<https://juniperpublishers.com/online-submission.php>